Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys-Reference-Cited by-同舟云学术

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

Published:2015-07-17 Issue:6245 Volume:349 Page:320-324
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Barouch Dan H.¹²,Alter Galit²,Broge Thomas²,Linde Caitlyn²,Ackerman Margaret E.³,Brown Eric P.³,Borducchi Erica N.¹,Smith Kaitlin M.¹,Nkolola Joseph P.¹,Liu Jinyan¹,Shields Jennifer¹,Parenteau Lily¹,Whitney James B.¹,Abbink Peter¹,Ng’ang’a David M.¹,Seaman Michael S.¹,Lavine Christy L.¹,Perry James R.¹,Li Wenjun⁴,Colantonio Arnaud D.⁵,Lewis Mark G.⁶,Chen Bing⁷,Wenschuh Holger⁸,Reimer Ulf⁸,Piatak Michael⁹,Lifson Jeffrey D.⁹,Handley Scott A.¹⁰,Virgin Herbert W.¹⁰,Koutsoukos Marguerite¹¹,Lorin Clarisse¹¹,Voss Gerald¹¹,Weijtens Mo¹²,Pau Maria G.¹²,Schuitemaker Hanneke¹²

Affiliation:

1. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

2. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.

3. Thayer School of Engineering at Dartmouth, Hanover, NH 03755, USA.

4. University of Massachusetts Medical School, Worcester, MA 01605, USA.

5. New England Primate Research Center, Southborough, MA 01772, USA.

6. Bioqual, Rockville, MD 20852, USA.

7. Children’s Hospital, Boston, MA 02115, USA.

8. JPT Peptide Technologies GmbH, 12489 Berlin, Germany.

9. AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.

10. Washington University School of Medicine, St. Louis, MO 63110, USA.

11. GSK Vaccines, 1330 Rixensart, Belgium.

12. Janssen Infectious Diseases and Vaccines (formerly Crucell), 2301 Leiden, Netherlands

Abstract

To defeat SIV, add a protein boost Despite 30 years of effort, no HIV-1 vaccine exists. Barouch et al. evaluated one promising strategy in rhesus macaques, a preclinical model commonly used to test potential HIV-1 vaccine candidates. They immunized monkeys with adenovirus-36 vectors engineered to express SIV (simian immunodeficiency virus) genes and then boosted them with a recombinant gp120 envelope glycoprotein (Env) from SIV. This regimen afforded greater protection than a strategy that instead used a viral vector–based boost. A parallel trial using a SHIV (simian/human immunodeficiency virus)–based vaccine and challenge model produced similar results. Whether this particular approach will be equally successful in humans remains to be tested. Science , this issue p. 320

Funder

NIH

Bill and Melinda Gates Foundation

Ragon Institute of MGH

Ragon Institute of MIT

Ragon Institute of Harvard

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference37 articles.

1. Ending AIDS — Is an HIV Vaccine Necessary?